Ruti Aga Gets Six-Year Ban: The Fake Prescription That Turned a Two-Year Sanction Into Six

On a March morning at a half marathon in China, Ruti Aga crossed the line first. Then came the sample, then the result. The prescription she placed before the anti-doping panel came from a clinic that did not exist; the "doctor" who issued it was a family member with no medical registration. According to the Athletics Integrity Unit (AIU) statement released on Thursday, six years of ineligibility rest on that single letter: two years for the substance, four for tampering with the evidence trail. First, the technical point that must precede any argument. Methylprednisolone is not a "steroid," as early reports described it. It is a glucocorticoid, WADA Prohibited List class S9, and it is prohibited in-competition only, by injection, oral or rectal routes. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only when residues are present on race day. The entire case therefore hinged on route and timing, not on the substance. And that is precisely where Aga defeated herself. One of my habits: before a race I read the stadium, then the results sheet. In this case the stadium is not a track but a prescription pad, and the pad tells you what was missing around the athlete. No credentialed team physician. No application for a therapeutic use exemption. No written guidance on route or washout. When all three vanish for a distance runner, what remains in the sport is one person and an old slip of paper. Consider the age: 32. In women's marathon that is the stage where the PB curve flattens and the body starts collecting its debts. The half marathon she won in March has no time recorded in the report, no splits, no field strength, no season's best. Inferring form from what is not there is the same error as predicting a marathon from the first kilometre split. The facts are only these: the race was won, the sample was taken, the substance was found. Now the arithmetic of the sanction. Two years for presence, which typically indicates the panel found the substance prohibited but intent unproven. Four years for tampering, the Code's standard penalty for a fabricated explanation. Two plus four, six. Note what follows. Had the prescription been genuine, the presence charge could have been argued at the no-fault or no-significant-fault end: potentially a reprimand, a heavily reduced period, and no tampering charge at all. The forged document destroyed the one defence the law allowed. What emerges is not an athlete's lapse but a system's empty space. Chronic knee pathology is not a rare coincidence among marathoners; it is close to an occupational hazard after 180 to 200 kilometres a week. And running through injury often becomes an economic necessity: appearance fees and prize money on the Chinese and Gulf label circuit are large enough that missing one race feels like losing months of income. Under that pressure, the cheapest and most available tool for masking pain is a glucocorticoid injection. What is absent is the structure that tells an athlete when to take it and when to stop. I think of an old frame. In 2026 I filmed a 400m time trial at NIS Patiala: two runners, 52.31 and 52.44, six lanes, zero spectators, fourteen masked staff. The microphone caught only spikes, breathing and silence. Commissioners first called it "too empty," then used it as an example. Emptiness plays the same role here: what was not there, the team doctor, the exemption, the file, is the actual story. The race time, the PB, the form all became secondary. The counter-argument matters too, because no easy moral emerges. A six-year ban rests on a substance with no proven endurance benefit; glucocorticoids reduce pain and inflammation, they do not raise lung capacity or muscle force. Comparing this to anabolic steroid cases would be dishonest, and the media were dishonest when they labelled it a steroid. But document forgery is not a technicality. It is evidence of deliberate concealment, and the Code treats it with matching severity. Those who question AIU rigour forget that had the panel accepted a family member's prescription, a fake note would become the cheapest defence available to every injured athlete. This pattern is not new in East African road racing. The enforcement frontier has shifted from catching samples to verifying documents, and China's label circuit, where large appearance fees, deep East African fields and AIU scrutiny converge, will be the most inspected territory ahead. The question is not whether Aga's 2026 Tokyo Marathon title and three World Marathon Major runner-up finishes prove her quality; they do, and the ban does not automatically reach back to them absent proof of earlier use. The question is whether the next 30-something marathoner who takes a knee injection before a Chinese label race will call a team doctor first, or a relative. Aga's exit changes nothing in Ethiopian women's marathon depth: three more 2:18 runners will stand there next season. What can change is whether their agents and training groups accept that the cheapest defence has become the most expensive.